TRACON Pharmaceuticals, Inc. (TCON)

NASDAQ: TCON · IEX Real-Time Price · USD
1.820
-0.140 (-7.14%)
At close: Apr 22, 2024, 4:00 PM
1.860
+0.040 (2.20%)
After-hours: Apr 22, 2024, 7:40 PM EDT
-7.14%
Market Cap 82.82M
Revenue (ttm) 12.05M
Net Income (ttm) -3.59M
Shares Out 45.50M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 142,112
Open 1.910
Previous Close 1.960
Day's Range 1.700 - 1.940
52-Week Range 1.590 - 36.800
Beta 1.04
Analysts Strong Buy
Price Target 60.00 (+3,196.7%)
Earnings Date May 8, 2024

About TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also in... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 30, 2015
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TCON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for TCON stock is "Strong Buy." The 12-month stock price forecast is $60.0, which is an increase of 3,196.70% from the latest price.

Price Target
$60.0
(3,196.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

TRACON Pharmaceuticals Announces Reverse Stock Split

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform...

14 days ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...

6 weeks ago - GlobeNewsWire

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

7 weeks ago - GlobeNewsWire

TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, De...

4 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

5 months ago - GlobeNewsWire

TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

6 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 Full ENVASARC accrual expected in Q4 and final data expected in mid-2024

7 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...

8 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

9 months ago - GlobeNewsWire

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

9 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference

SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...

11 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...

11 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

11 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development plat...

1 year ago - GlobeNewsWire

TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development plat...

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...

1 year ago - GlobeNewsWire

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

Initial $3.5M Funding Maintains Cash Runway of Mid-2023 Initial $3.5M Funding Maintains Cash Runway of Mid-2023

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned

Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...

1 year ago - GlobeNewsWire